search
Back to results

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Primary Purpose

Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
NC-503 (Anti-amyloidotic (AA) Agent)
Sponsored by
Bellus Health Inc
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Secondary (AA) Amyloidosis focused on measuring Familial Mediterranean Fever, Amyloidosis, Secondary (AA) Amyloidosis, Nephrotic Syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

PROTOCOL INCLUSION CRITERIA Patients must be 18 years of age or older. Males and females. If women of childbearing potential (i.e., not surgically sterilized or post-menopausal greater than one year) the patient must be using effective birth control. Diagnosis of AA amyloidosis demonstrated by positive biopsy (Congo red staining) and immunohistochemistry or immunoelectron microscopy at screening visit. Tissue from previous biopsy can be used for confirmation of diagnosis, if available. Persistent proteinuria defined as urinary protein excretion ? 1g/24h in two distinct 24-h urine collections at least 1 week apart within 3 months prior to study entry (baseline, Month 0 visit) without evidence of urinary tract infection or overt heart failure (NYHA class III or more); OR creatinine clearance ? 60 mL/min in two distinct measures at least 1 week apart within 3 months prior to study entry (baseline, Month 0 visit). Creatinine clearance ? 20 mL/min AND serum creatinine ? 3 mg/dl within 3 months prior to study entry (baseline, Month 0 visit). Written informed consent. PROTOCOL EXCLUSION CRITERIA Evidence or suspicion of renal or renovascular diseases other than renal AA amyloidosis. Presence of diabetes mellitus (Type I and II). Evidence of a cause of potentially reversible reduced renal function, such as accelerated hypertension or drug nephrotoxicity. AST, ALT, or ALP > 5 times the upper limit of normal, or total bilirubin 50% above upper limits of normal. Presence of any other clinically significant diseases that could interfere with the interpretation of study results or compromise patient safety or any conditions that could reduce life expectancy to less than two years. Use of an investigational drug within thirty days prior to the screening visit. Active alcohol and/or drug abuse. Initiation of or any changes in ACE inhibitor therapy within 3 months prior to the screening visit. Initiation of or any changes in cytotoxic agents/colchicine therapy within 3 months prior to the screening visit. Inability to provide legal consent.

Sites / Locations

  • Indiana University School of Medicine, Department of Pathology and Laboratory Medicine,
  • Boston Medical Center, Renal Division
  • Mayo Clinic
  • Mount Sinai Medical Center
  • Rheumatism Foundation Hospital
  • Centre Hospitalier du Mans, Service de Rhumatologie
  • Hôpital Claude Huriez, Service de médecine Interne, Clinique Médicale A
  • Hôpital Cochin, Centre de Recherche et d'Explorations Fonctionnelles
  • Bnai Zion Medical Center
  • Heller Institute of Medical Research, Sheba Medical Center
  • Italian Group for Systemic Amyloidosis, Biotechnology Research Laboratories, IRCCS Policlinico San Matteo, Internal Medicine and Medical Oncology
  • Vilnius University Hospital
  • University Hospital Groningen, Department of Medicine, Division of Rheumatology
  • Instytut Reumatologiczny
  • Okregowy Szpital Kolejowy, Zaklad Reumatologii
  • Institute of Rheumatology RAMS
  • Regional Hospital No. 1
  • Hospital Universitario Germans Trias I Pujol, Servicio de Reumatologia
  • Hospital Clinic I Provincial de Barcelona, Jefe del Departamento de Reumatologia
  • Ciutad Sanitària y Universitària de Bellvitge, Servicio de Reumatologia, Hospitalet de Llobregat
  • Hospital Clinico San Carlos de Madrid, Servicio de Reumatologia
  • Cerrehpasa Tip Fakultesi
  • Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology
  • Marmara University Medical School Hospital, Department of Rheumatology
  • Royal Free and University College Medical School, Department of Medicine, National Amyloidosis Centre
  • Gartnavel General Hospital

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
May 2, 2002
Last Updated
February 13, 2006
Sponsor
Bellus Health Inc
Collaborators
FDA Office of Orphan Products Development
search

1. Study Identification

Unique Protocol Identification Number
NCT00035334
Brief Title
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Official Title
A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2006
Overall Recruitment Status
Completed
Study Start Date
October 2001 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2004 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Bellus Health Inc
Collaborators
FDA Office of Orphan Products Development

4. Oversight

5. Study Description

Brief Summary
The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical improvement/worsening of both renal and gastrointestinal functions.
Detailed Description
AA amyloidosis is associated with chronic inflammatory conditions (rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease), chronic infection (tuberculosis, osteomyelitis), and Familial Mediterranean Fever. Rheumatoid arthritis is the major cause of AA amyloidosis in Western Europe and North America. The most common clinical feature of AA amyloidosis is renal dysfunction manifested as nephrotic-range proteinuria or renal insufficiency at the time of diagnosis. End-stage renal failure is the cause of death in 40-60% of cases. Gastrointestinal involvement is also frequent and is usually manifested as chronic diarrhea, body weight loss and malabsorption. Enlargement of the liver and spleen may also occur in some patients. The median survival time from diagnosis varies from 2 to 8 years depending on the stage of the disease at time of diagnosis. The goal of the current therapy in AA amyloidosis is the control of the associated disease. However, the current approaches for the treatment of AA amyloidosis are unspecific, toxic, invasive, and not sufficiently effective in many cases. NC-503 was specifically designed to compete with the naturally occurring sulfated GAGs for the binding to amyloidogenic precursor proteins, and to inhibit amyloid deposition into tissues. The proposed therapy with NC-503 is based on the prevention of the amyloid fibril formation. The objective of this clinical phase II/III study is to determine the efficacy and safety of NC-503 compared to a placebo in patients suffering from secondary (AA) amyloidosis by the assessment of clinical improvement/ worsening of both renal and gastrointestinal functions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome, Kidney Diseases, Gastrointestinal Diseases
Keywords
Familial Mediterranean Fever, Amyloidosis, Secondary (AA) Amyloidosis, Nephrotic Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
150 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
NC-503 (Anti-amyloidotic (AA) Agent)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
PROTOCOL INCLUSION CRITERIA Patients must be 18 years of age or older. Males and females. If women of childbearing potential (i.e., not surgically sterilized or post-menopausal greater than one year) the patient must be using effective birth control. Diagnosis of AA amyloidosis demonstrated by positive biopsy (Congo red staining) and immunohistochemistry or immunoelectron microscopy at screening visit. Tissue from previous biopsy can be used for confirmation of diagnosis, if available. Persistent proteinuria defined as urinary protein excretion ? 1g/24h in two distinct 24-h urine collections at least 1 week apart within 3 months prior to study entry (baseline, Month 0 visit) without evidence of urinary tract infection or overt heart failure (NYHA class III or more); OR creatinine clearance ? 60 mL/min in two distinct measures at least 1 week apart within 3 months prior to study entry (baseline, Month 0 visit). Creatinine clearance ? 20 mL/min AND serum creatinine ? 3 mg/dl within 3 months prior to study entry (baseline, Month 0 visit). Written informed consent. PROTOCOL EXCLUSION CRITERIA Evidence or suspicion of renal or renovascular diseases other than renal AA amyloidosis. Presence of diabetes mellitus (Type I and II). Evidence of a cause of potentially reversible reduced renal function, such as accelerated hypertension or drug nephrotoxicity. AST, ALT, or ALP > 5 times the upper limit of normal, or total bilirubin 50% above upper limits of normal. Presence of any other clinically significant diseases that could interfere with the interpretation of study results or compromise patient safety or any conditions that could reduce life expectancy to less than two years. Use of an investigational drug within thirty days prior to the screening visit. Active alcohol and/or drug abuse. Initiation of or any changes in ACE inhibitor therapy within 3 months prior to the screening visit. Initiation of or any changes in cytotoxic agents/colchicine therapy within 3 months prior to the screening visit. Inability to provide legal consent.
Facility Information:
Facility Name
Indiana University School of Medicine, Department of Pathology and Laboratory Medicine,
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
Boston Medical Center, Renal Division
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Mount Sinai Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Rheumatism Foundation Hospital
City
Heinola
ZIP/Postal Code
FIN-18120
Country
Finland
Facility Name
Centre Hospitalier du Mans, Service de Rhumatologie
City
Le Mans
ZIP/Postal Code
CEDEX 1
Country
France
Facility Name
Hôpital Claude Huriez, Service de médecine Interne, Clinique Médicale A
City
Lille
ZIP/Postal Code
CEDEX 59037
Country
France
Facility Name
Hôpital Cochin, Centre de Recherche et d'Explorations Fonctionnelles
City
Paris
ZIP/Postal Code
75679 CEDEX 14
Country
France
Facility Name
Bnai Zion Medical Center
City
Haifa
ZIP/Postal Code
31048
Country
Israel
Facility Name
Heller Institute of Medical Research, Sheba Medical Center
City
Tel Hashomer
ZIP/Postal Code
52621
Country
Israel
Facility Name
Italian Group for Systemic Amyloidosis, Biotechnology Research Laboratories, IRCCS Policlinico San Matteo, Internal Medicine and Medical Oncology
City
Pavia
ZIP/Postal Code
27100
Country
Italy
Facility Name
Vilnius University Hospital
City
Vilnius
ZIP/Postal Code
2001
Country
Lithuania
Facility Name
University Hospital Groningen, Department of Medicine, Division of Rheumatology
City
Groningen
ZIP/Postal Code
9700 RB
Country
Netherlands
Facility Name
Instytut Reumatologiczny
City
Warszawa
ZIP/Postal Code
02-632
Country
Poland
Facility Name
Okregowy Szpital Kolejowy, Zaklad Reumatologii
City
Wroclaw
ZIP/Postal Code
53-137
Country
Poland
Facility Name
Institute of Rheumatology RAMS
City
Moscow
ZIP/Postal Code
115522
Country
Russian Federation
Facility Name
Regional Hospital No. 1
City
Yekaterinburg
ZIP/Postal Code
320102
Country
Russian Federation
Facility Name
Hospital Universitario Germans Trias I Pujol, Servicio de Reumatologia
City
Badalona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Hospital Clinic I Provincial de Barcelona, Jefe del Departamento de Reumatologia
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Ciutad Sanitària y Universitària de Bellvitge, Servicio de Reumatologia, Hospitalet de Llobregat
City
Llobregat
ZIP/Postal Code
08907
Country
Spain
Facility Name
Hospital Clinico San Carlos de Madrid, Servicio de Reumatologia
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Cerrehpasa Tip Fakultesi
City
Askaray, Istanbul, Turkey
Country
Turkey
Facility Name
Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology
City
Istanbul
ZIP/Postal Code
34390 CAPA
Country
Turkey
Facility Name
Marmara University Medical School Hospital, Department of Rheumatology
City
Uskudar, Altunizade, Istanbul
ZIP/Postal Code
81190
Country
Turkey
Facility Name
Royal Free and University College Medical School, Department of Medicine, National Amyloidosis Centre
City
London
ZIP/Postal Code
NW3 2PF
Country
United Kingdom
Facility Name
Gartnavel General Hospital
City
Scotland
ZIP/Postal Code
G12 0YN
Country
United Kingdom

12. IPD Sharing Statement

Citations:
Citation
Safety, Tolerability and Pharmacokinetic Profile of FibrillexTM (Anti-AA Amyloid Agent) in Healthy and Renal Impaired Subjects. Garceau D., Gurbindo C., Laurin J. Neurochem Inc. Reference: Proceedings from the IXth International Symposium on Amyloidosis , 2001 (Budapest, Hungary)
Results Reference
background
PubMed Identifier
17554116
Citation
Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puechal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M; Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2349-60. doi: 10.1056/NEJMoa065644.
Results Reference
derived

Learn more about this trial

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

We'll reach out to this number within 24 hrs